Esther Llagostera
Overview
Explore the profile of Esther Llagostera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
352
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanders T, Llagostera E, Barna M
Nature
. 2013 Apr;
497(7451):628-32.
PMID: 23624372
The ability of signalling proteins to traverse tissues containing tightly packed cells is of fundamental importance for cell specification and tissue development; however, how this is achieved at a cellular...
2.
Llagostera E, Alvarez Lopez M, Scimia C, Catalucci D, Parrizas M, Ruiz-Lozano P, et al.
Muscle Nerve
. 2011 Dec;
45(1):128-30.
PMID: 22190319
The protein kinase product of the gene mutated in myotonic dystrophy 1 (DMPK) is reported to play a role in cardiac pathophysiology. To gain insight into the molecular mechanisms modulated...
3.
Llagostera E, Carmona M, Vicente M, Escorihuela R, Kaliman P
FEBS Lett
. 2009 Jun;
583(12):2121-5.
PMID: 19482024
Myotonic dystrophy 1 (MD1) is caused by a CTG expansion in the 3'-unstranslated region of the myotonic dystrophy protein kinase (DMPK) gene. MD1 patients frequently present insulin resistance and increased...
4.
Kaliman P, Llagostera E
Cell Signal
. 2008 Jun;
20(11):1935-41.
PMID: 18583094
Myotonic dystrophy 1 (DM1) is an autosomal, dominant inherited, neuromuscular disorder. The DM1 mutation consists in the expansion of an unstable CTG-repeat in the 3'-untranslated region of a gene encoding...
5.
Llagostera E, Catalucci D, Marti L, Liesa M, Camps M, Ciaraldi T, et al.
PLoS One
. 2007 Nov;
2(11):e1134.
PMID: 17987120
Myotonic dystrophy 1 (DM1) is caused by a CTG expansion in the 3'-unstranslated region of the DMPK gene, which encodes a serine/threonine protein kinase. One of the common clinical features...
6.
Llagostera E, Soto-Cerrato V, Joshi R, Montaner B, Gimenez-Bonafe P, Perez-Tomas R
Anticancer Drugs
. 2005 Mar;
16(4):393-9.
PMID: 15746575
In the present study, we describe the cytotoxicity of the new drug prodigiosin (PG) in two small cell lung carcinoma (SCLC) cell lines, GLC4 and its derived doxorubicin-resistant GLC4/ADR cell...
7.
Soto-Cerrato V, Llagostera E, Montaner B, Scheffer G, Perez-Tomas R
Biochem Pharmacol
. 2004 Sep;
68(7):1345-52.
PMID: 15345324
Prodigiosin (PG) is a red pigment produced by Serratia marcescens with pro-apoptotic activity in haematopoietic and gastrointestinal cancer cell lines, but no marked toxicity in non-malignant cells. Breast cancer is...
8.
Llagostera E, Soto-Cerrato V, Montaner B, Perez-Tomas R
Ann N Y Acad Sci
. 2004 Mar;
1010:178-81.
PMID: 15033716
Prodigiosin (PG) is a secondary metabolite, isolated from a culture of Serratia marcescens, which has shown potent cytotoxicity against various human cancer cell lines as well as immunosuppressive activity. The...
9.
Perez-Tomas R, Montaner B, Llagostera E, Soto-Cerrato V
Biochem Pharmacol
. 2003 Oct;
66(8):1447-52.
PMID: 14555220
The family of natural red pigments, called prodigiosins (PGs), characterised by a common pyrrolylpyrromethene skeleton, are produced by various bacteria. Some members have immunosuppressive properties and apoptotic effects in vitro...